Exagen Inc. has reached a major milestone by completing its 1,000,000th AVISE CTD test, a diagnostic tool for autoimmune and connective tissue diseases. This achievement highlights the company’s ...
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. There's PBC, there's PSC, and then there's ...
SAN DIEGO, California, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Johns Hopkins University jointly announced today the ...
CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the validation and regulatory submission for approval of new Systemic Lupus ...
Delivered record total revenue of $15.5 million on the strength of continued ASP expansion and AVISE CTD test volume growth. Expanded AVISE CTD trailing twelve-month ASP to $419, an increase of $42 ...
Autoimmune rheumatic diseases (ARDs) represent a diverse group of conditions in which the immune system mistakenly targets the body’s own tissues, often affecting the musculoskeletal system and ...
SAN DIEGO, May 24, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the William Blair 41st Annual Growth ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback